MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)

Phase 1
Completed
Conditions
Arthritis, Rheumatoid
Interventions
Drug: High dose of BIIL 284 BS tablets
Drug: Low dose of BIIL 284 BS tablets
Drug: Placebo
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
26
Registration Number
NCT02247375

Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers

First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
60
Registration Number
NCT02249416

Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease

Completed
Conditions
Parkinson Disease
Interventions
Drug: Pramipexole
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1449
Registration Number
NCT02248168

The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: BIIL 284 BS
Drug: Placebo
First Posted Date
2014-09-25
Last Posted Date
2014-09-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
38
Registration Number
NCT02249312

Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

Completed
Conditions
Parkinson Disease
Interventions
Drug: Pramipexole
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1293
Registration Number
NCT02248207

Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: TPV low
Drug: Placebo
Drug: TPV high
Drug: Moxifloxacin
Drug: RTV
First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
81
Registration Number
NCT02248883

Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 409306
Drug: Itraconazole
First Posted Date
2014-09-25
Last Posted Date
2024-04-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
25
Registration Number
NCT02248259
Locations
🇰🇷

1289.23.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency

Phase 1
Completed
Conditions
Hepatic Insufficiency
Interventions
Drug: Tipranavir (TPV)
Drug: Ritonavir (r)
First Posted Date
2014-09-25
Last Posted Date
2014-09-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02249442

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

First Posted Date
2014-09-25
Last Posted Date
2014-09-25
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT02249130

Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Low dose of BIIL 284 BS tablets
Drug: Medium dose of BIIL 284 BS tablets
Drug: High dose of BIIL 284 BS tablets
Drug: Placebo
First Posted Date
2014-09-25
Last Posted Date
2014-09-26
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
577
Registration Number
NCT02249247
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy